Keros Therapeutics (KROS) Capital Expenditures Growth (3y) (2022 - 2025)
Keros Therapeutics (KROS) Capital Expenditures Growth (3y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 16.27% |
| 10 | Keros Therapeutics | 384.68 Mn | 97.28 Mn | - | 192.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 192.15% |
| Sep 30, 2025 | -22.23% |
| Jun 30, 2025 | 4.72% |
| Mar 31, 2025 | 86.57% |
| Dec 31, 2024 | 22.04% |
| Sep 30, 2024 | -23.58% |
| Jun 30, 2024 | 90.25% |
| Mar 31, 2024 | 3.08% |
| Sep 30, 2023 | 67.46% |
| Jun 30, 2023 | 264.14% |
| Mar 31, 2023 | -50.77% |
| Dec 31, 2022 | 51.02% |
| Sep 30, 2022 | -119.31% |
| Jun 30, 2022 | 54.20% |